RBC Capital Markets on Monday issued a note on the specialty pharma space highlighting Mylan NV (NASDAQ: MYL) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) ahead of the companies' earnings announcements on Wednesday and Thursday, respectively. Analyst Randall Stanicky gave his opinion on the two companies.

Mylan

"We expect a solid EPIPEN driven 4Q and are $0.03 above consensus at $1.30. MYL has been pointing to the upper end of its $4.15 to $4.35 range for 2015 which implies 4Q EPS towards $1.31."

RBC believes that investors should focus on Mylan's message on capital deployment following the attempted hostile takeover of Perrigo Company (NYSE: PRGO) and the likelihood of a transformational deal during 2016, which has the potential to drive top-line growth.

Teva

"We expect solid results out of TEVA despite our $1.26 4Q EPS forecast being $0.03 below consensus. However, we do not expect 2016 guidance until 1Q2016 in early May which will follow the closing of the AGN generics deal we expect will come in Mar at this point."

RBC noted that investors should focus on several updates regarding the company's drug pipeline including SD-809 PDUFA in late May. These clinical trials have the potential to drive growth for the company in the near term.

Latest Ratings for MYL

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

See more from Benzinga

• Checks Following FireEye's 'Momentum' Conference Show Event Was 'Strong'

• Oppenheimer Upgrades Amedisys To Outperform, Sets Target

• Stifel Nicolaus Upgrades Big 5 Sporting Goods To Buy

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.